Plain-English translation of NCT07188896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining three immune-boosting drugs—, , and —or two of those drugs together work better than the current standard treatment for advanced kidney cancer. The study will compare these new combinations to the standard treatment that is typically given first to kidney cancer patients. Researchers hope that by combining these immune-boosting medications in different ways, they can help the body's own immune system fight the cancer more effectively.
While existing immune treatments help some kidney cancer patients, doctors are looking for ways to make these treatments work better and help more people. This trial explores whether combining this medication with other immune-boosting drugs could improve outcomes for people with advanced kidney cancer.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to one of three groups receiving different combinations of intravenous medications. All treatments are given by IV infusion at the hospital or clinic. You will have regular visits for treatment administration, blood tests, and imaging scans to monitor how the cancer responds. The trial will involve ongoing medical care over several months, with your research team monitoring you closely for how well the treatment works and for any side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States